
CVSA Stock Forecast & Price Target
CVSA Analyst Ratings
Bulls say
Covista is projected to experience strong revenue growth and potentially surpass earnings estimates due to its focus on nursing and healthcare education, along with its partnership with Sallie Mae to address new loan caps. However, potential challenges in recruiting and pricing power could lead to a slowdown in growth if enrollment targets are not met. Despite this risk, the company's focus on operational excellence and goal to reach 65,000 students by FY/29 make it an attractive investment opportunity with an OUTPERFORM rating and a price target of $170, reflecting its potential for premium valuation in the future.
Bears say
Covista is a for-profit educator with a majority of its revenue coming from clinical healthcare education. Despite macro tailwinds in healthcare education, Covista's exposure to the for-profit sector and a history of regulatory challenges raises concerns about future growth potential. Additionally, the company's low composite score could limit its ability to make future acquisitions and its high level of capital return could constrain future investments in campus expansions.
This aggregate rating is based on analysts' research of Adtalem Global Education Inc and is not a guaranteed prediction by Public.com or investment advice.
CVSA Analyst Forecast & Price Prediction
Start investing in CVSA
Order type
Buy in
Order amount
Est. shares
0 shares